NO20050113L - Sekundaere amino-aniliniske piperidiner som MCH1-antagonister og anvendelser derav - Google Patents

Sekundaere amino-aniliniske piperidiner som MCH1-antagonister og anvendelser derav

Info

Publication number
NO20050113L
NO20050113L NO20050113A NO20050113A NO20050113L NO 20050113 L NO20050113 L NO 20050113L NO 20050113 A NO20050113 A NO 20050113A NO 20050113 A NO20050113 A NO 20050113A NO 20050113 L NO20050113 L NO 20050113L
Authority
NO
Norway
Prior art keywords
compound
subject
provides
treating
pharmaceutically acceptable
Prior art date
Application number
NO20050113A
Other languages
English (en)
Inventor
John M Wetzel
John E Deleon
Yu Jiang
Chien-An Chen
Kai Lu
Mohammad Marzabadi
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20050113L publication Critical patent/NO20050113L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Denne oppfinnelse er rettet mot forbindelser som er selektive antagonister for melanin-konsentrerende hormon-1 (MCH1)-reseptorer. Oppfinnelsen tilveiebringer en farmasøytisk sammensetning omfattende en terapeutisk effektiv mengde av forbindelsen av oppfinnelsen og en farmasøytisk akseptabel bærer. Denne oppfinnelse tilveiebringer en farmasøytisk sammensetning laget ved å kombinere en terapeutisk effektiv mengde av forbindelsen av denne oppfinnelse og en farmasøytisk akseptabel bærer. Denne oppfinnelse tilveiebringer videre en fremgangsmåte for å lage en farmasøytisk sammensetning omfattende å kombinere en terapeutisk effektiv mengde av forbindelsen av oppfinnelsen og en farmasøytisk akseptabel bærer. Denne oppfinnelse tilveiebringer også en fremgangsmåte for å redusere kroppsmassen til et individ hvilken omfatter å administrere til individet en mengde av en forbindelse av oppfinnelsen effektiv for å redusere individets kroppsmasse. Denne oppfinnelse tilveiebringer ytterligere en fremgangsmåte for å behandle et individ som lider av depresjon og/eller angst hvilken omfatter å administrere til individet en mengde av en forbindelse av oppfinnelsen effektiv for å behandle individets depresjon og/eller angst. Denne oppfinnelse tilveiebringer ytterligere en fremgangsmåte for å behandle et individ som lider av en urinveislidelse.
NO20050113A 2002-07-03 2005-01-10 Sekundaere amino-aniliniske piperidiner som MCH1-antagonister og anvendelser derav NO20050113L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18914502A 2002-07-03 2002-07-03
PCT/US2003/021391 WO2004005257A1 (en) 2002-07-03 2003-07-03 Secondary amino anilinic piperidines as mch1 antagonists and uses thereof

Publications (1)

Publication Number Publication Date
NO20050113L true NO20050113L (no) 2005-01-10

Family

ID=30114020

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050113A NO20050113L (no) 2002-07-03 2005-01-10 Sekundaere amino-aniliniske piperidiner som MCH1-antagonister og anvendelser derav

Country Status (19)

Country Link
US (1) US7473698B2 (no)
EP (1) EP1556351A4 (no)
JP (1) JP2005532399A (no)
KR (1) KR20050034710A (no)
CN (1) CN1319945C (no)
AU (1) AU2003259098A1 (no)
BR (1) BR0312257A (no)
CA (1) CA2485379A1 (no)
EA (1) EA008826B1 (no)
HK (1) HK1080471A1 (no)
IL (1) IL165730A0 (no)
IS (1) IS7560A (no)
MX (1) MXPA04012103A (no)
NO (1) NO20050113L (no)
NZ (1) NZ536329A (no)
PL (1) PL373621A1 (no)
UA (1) UA77536C2 (no)
WO (1) WO2004005257A1 (no)
ZA (1) ZA200409425B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199135B2 (en) 2001-07-05 2007-04-03 H. Lundbeck A/S Substituted alkyl amido piperidines
US7105544B2 (en) 2001-07-05 2006-09-12 Synaptic Pharmaceutical Corporation Substituted alkyl amido piperidines
US20050154020A1 (en) * 2004-01-14 2005-07-14 Synaptic Pharmaceutical Corporation 4-Aryl piperidines
US20050154022A1 (en) * 2004-01-14 2005-07-14 H. Lundbeck A/S 4-aryl piperidines
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
US7329656B2 (en) 2004-10-08 2008-02-12 H. Lundbeck A/S Arylthiobenzylpiperidine derivatives
US20060079683A1 (en) * 2004-10-08 2006-04-13 Marzabadi Mohammad R Arylthiobenzylpiperidine derivatives
US7446204B2 (en) 2004-10-08 2008-11-04 H. Lundbeck A/S Amino substituted aryloxybenzylpiperidine derivatives
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
BR112018015389B1 (pt) 2016-03-17 2023-12-19 F. Hoffmann-La Roche Ag Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
FR2744448B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
US6326381B1 (en) * 1998-12-17 2001-12-04 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetrahydropyidine amide derivates
US20030082623A1 (en) * 1998-12-31 2003-05-01 Beth Borowsky DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
JP2004504303A (ja) * 2000-07-05 2004-02-12 シナプティック・ファーマスーティカル・コーポレーション 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用
EP1246847A2 (en) * 2000-07-05 2002-10-09 Synaptic Pharmaceutical Corporation Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
US6953801B2 (en) 2001-05-22 2005-10-11 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
JP2004536104A (ja) 2001-07-05 2004-12-02 シナプティック・ファーマスーティカル・コーポレーション Ｍｃｈ選択的アンタゴニストとしての置換されたアニリン−ピペリジン誘導体

Also Published As

Publication number Publication date
KR20050034710A (ko) 2005-04-14
CA2485379A1 (en) 2004-01-15
US7473698B2 (en) 2009-01-06
EA200500152A1 (ru) 2005-06-30
CN1319945C (zh) 2007-06-06
ZA200409425B (en) 2006-04-26
WO2004005257A1 (en) 2004-01-15
IS7560A (is) 2004-11-26
IL165730A0 (en) 2006-01-15
NZ536329A (en) 2007-06-29
US20050245743A1 (en) 2005-11-03
AU2003259098A1 (en) 2004-01-23
JP2005532399A (ja) 2005-10-27
EA008826B1 (ru) 2007-08-31
CN1665786A (zh) 2005-09-07
BR0312257A (pt) 2005-04-12
EP1556351A4 (en) 2007-07-25
PL373621A1 (en) 2005-09-05
MXPA04012103A (es) 2005-04-19
UA77536C2 (en) 2006-12-15
EP1556351A1 (en) 2005-07-27
HK1080471A1 (en) 2006-04-28

Similar Documents

Publication Publication Date Title
NO20050113L (no) Sekundaere amino-aniliniske piperidiner som MCH1-antagonister og anvendelser derav
NO20053838L (no) Substituerte alkyl-amido-piperidiner
NO20050145L (no) Spirocykliske piperidiner som MCH1-antagonister og anvendelser derav
EA200100136A1 (ru) Предотвращение образования слизистого секрета в дыхательных путях посредством введения антагонистов рецепторов эпидермального фактора роста (egf-r)
ATE450260T1 (de) Therapeutische zusammensetzungen enthaltend 1,2,3,6-tetrahydropyrimidin-2-one und entsprechende methoden
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
MXPA03007853A (es) Metodo para la sintesis de 2',3'-didesoxi-2',3'-dideshidronucleosidos.
NO20051048L (no) Terapeutisk humant anti-IL-1R1 monoklonalt antistoff
BG110227A (en) USE OF MODULATORS OF THE GLUCOCORTICOID RECEPTOR
AU2007349112A1 (en) Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
UA49796C2 (uk) Ангідрат пароксетин гідрохлориду, спосіб його одержання, сольвати пароксетин гідрохлориду, спосіб їх одержання, спосіб лікування та/або профілактики та фармацевтична композиція
HK1082728A1 (en) Azabicyclo derivatives as muscarinic receptor antagonists
NO20063650L (no) 4-aryl-piperidiner
BR0317370A (pt) Composição farmacêutica e método paliativo
WO2000020041A8 (en) Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent
BRPI0409302A (pt) derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
WO2007114902A3 (en) Alkylthiobenzylpiperidine compounds
DE69736833D1 (de) Steroide als neurochemische stimulatoren des nasenraumes zur linderung der prämenstrualen symptome
NO20080411L (no) Alkylsulfonamiddderivater
WO2007114916A3 (en) Arylbenzylpiperidine compounds
WO2004080411A3 (en) Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
WO2006041635A8 (en) Arylthiobenzylpiperidine derivatives
BRPI0413607A (pt) composição farmacêutica para a prevenção e tratamento do vìcio em mamìferos
Yunoki et al. Role of the M 2 muscarinic receptor pathway in lidocaine-induced potentiation of the relaxant response to atrial natriuretic peptide in bovine tracheal smooth muscle
BR0210869A (pt) Composto, composição farmacêutica, processo de preparar uma composição farmacêutica, métodos de tratar um indivìduo que sofre de um distúrbio, de depressão e de ansiedade, obesidade, bexiga hiperativa e um distúrbio em um indivìduo, de reduzir a massa corporal de um indivìduo e de aliviar incontinência de urgência urinária e os sintomas de um distúrbio em um indivìduo

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application